132 related articles for article (PubMed ID: 11763992)
1. Cisplatin-induced vomiting depends on circadian timing.
Kobayashi M; To H; Tokue A; Fujimura A; Kobayashi E
Chronobiol Int; 2001 Sep; 18(5):851-63. PubMed ID: 11763992
[TBL] [Abstract][Full Text] [Related]
2. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Tanimura S; Banba J; Tomoyasu H; Masaki M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
11. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
Krzakowski M; Graham E; Goedhals L; Joly F; Pawlicki M; Rapoport B; Yelle L; Lees J; McQuade B
Anticancer Drugs; 1998 Aug; 9(7):593-8. PubMed ID: 9773802
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Gebbia V; Testa A; Cannata G; Gebbia N
Anticancer Drugs; 1996 Sep; 7(7):734-7. PubMed ID: 8949983
[TBL] [Abstract][Full Text] [Related]
14. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
[TBL] [Abstract][Full Text] [Related]
16. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
[TBL] [Abstract][Full Text] [Related]
17. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Zeng WY
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
[TBL] [Abstract][Full Text] [Related]
18. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Liaw CC; Chang HK; Liau CT; Huang JS; Lin YC; Chen JS
Am J Clin Oncol; 2003 Feb; 26(1):12-5. PubMed ID: 12576917
[TBL] [Abstract][Full Text] [Related]
19. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women.
Franchi M; Donadello N; Zanaboni F; Tusei A; Scorbati E
Oncology; 1995; 52(6):509-12. PubMed ID: 7478441
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
